A5041487849- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Systemic Lupus Erythematosus Research
- Uterine Myomas and Treatments
- Hepatitis B Virus Studies
- Molecular Junctions and Nanostructures
- Surface and Thin Film Phenomena
- Nanoparticles: synthesis and applications
- Surgical Simulation and Training
- Surface Chemistry and Catalysis
- Immune Cell Function and Interaction
- Force Microscopy Techniques and Applications
- Physics of Superconductivity and Magnetism
- Maternal and fetal healthcare
- Cardiac, Anesthesia and Surgical Outcomes
- HIV Research and Treatment
Johns Hopkins University
2010-2024
Johns Hopkins Medicine
2020-2024
University of Baltimore
2022
Ohio University
2006-2010
Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement neutralizing breadth vaccine-induced antibodies. Currently available HCV panels may not adequately represent the genetic antigenic diversity circulating strains, lack standardization these makes it difficult to compare neutralization results obtained in different studies. Here, we describe selection validation genetically antigenically diverse reference panel 15 pseudoparticles...
Despite prolific efforts to characterize the antibody response human immunodeficiency virus type 1 (HIV-1) and hepatitis C (HCV) mono-infections, chronic co-infection with these two ever-evolving viruses is poorly understood. Here, we investigate repertoire of a chronically HIV-1/HCV co-infected individual using linking B cell receptor antigen specificity through sequencing (LIBRA-seq). We identify five cross-reactive antibodies demonstrating binding functional cross-reactivity between HIV-1...
Introduction Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance infection, so induction bNAbs a major goal HCV vaccine development. However, molecular antibody features important for broad neutralization are not known. Methods To identify B cell repertoire neutralization, we performed RNA sequencing receptors (BCRs) E2-reactive cells HCV-infected individuals either high or low...
Antibodies targeting the hepatitis C virus (HCV) envelope glycoprotein E2 are associated with delayed disease progression, and these antibodies can also facilitate spontaneous clearance of infection in some individuals. However, many infected people demonstrate low titer anti-E2 antibody responses. Since a goal HCV vaccine development is induction high titers antibodies, it important to define mechanisms underlying suboptimal By staining lymphocytes cocktail soluble (sE2) glycoproteins, we...
We demonstrate an atomic scale construction scheme, which is performed at area as small a few tens of nanometer square. In this site, all the basic building blocks, single atoms, are extracted locally using scanning-tunneling-microscope tip from substrate. These atoms then precisely positioned on surface to form desired structures. After completion construction, remaining debris removed and undesired holes near site filled with atoms/clusters tidy up area. This entire scheme closely...
Abstract Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance infection, so induction bNAbs a major goal HCV vaccine development. However, much remains to be learned at molecular level about protective E2-reactive antibodies, since infection persists in some individuals despite early plasma. To examine B cell repertoire features broad neutralization and viral clearance, we...